Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Radiation
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
—
Drugs
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile,
1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile,
1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine,
1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea,
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,
1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butyl-urea,
2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride,
2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate,
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}- 1H-pyrazol-3-yl)amino]- quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,
2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one,
225Ac-lintuzumab,
26 base single stranded phosphodiester DNA oligonucleotide,
5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine,
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate,
Allogeneic T cells encoding an exogenous TK gene,
Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2,
Allogeneic ex vivo expanded umbilical cord blood cells,
Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells,
Allogeneic human dendritic cells derived from a CD34+ progenitor cell line,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2,
Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells,
Alvocidib,
Amonafide L-malate,
Antisense oligonucleotide 5'-d[P-Thio} (CCCTG CTCCC CCCTG GCTCC)-3',
Arsenic trioxide
(
Arsenic Trioxide Accord,
Arsenic trioxide Mylan,
Arsenic trioxide medac,
TRISENOX
),
Azacitidine
(
AZACITIDINE ACCORD,
AZACITIDINE BETAPHARM,
AZACITIDINE CELGENE,
AZACITIDINE MYLAN,
VIDAZA
),
Bisantrene hydrochloride,
Clofarabine
(
CLOLAR,
EVOLTRA,
IVOZALL
),
Combretastatin A1 diphosphate-,
Crenolanib besylate,
Daunorubicin (liposomal),
Decitabine
(
DACOGEN
),
Devimistat,
Donor lymphocyte preparation depleted of functional alloreactive T-cells,
Enasidenib
(
IDHIFA
),
Entospletinib,
Eryaspase
(
GRASPA
),
Fully human IgG1 antibody specific for CD33,
Gemtuzumab Ozogamicin
(
MYLOTARG
),
Gilteritinib
(
XOSPATA
),
Glasdegib
(
DAURISMO
),
Guadecitabine,
Histamine dihydrochloride
(
CEPLENE
),
Homoharringtonine
(
CEFLATONIN
),
Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9),
Idasanutlin,
Inecalcitol,
Isocitrate dehydrogenase 2-mutant inhibitor,
Ivosidenib
(
TIBSOVO
),
L-Asparaginase
(
KIDROLASE,
SPECTRILA
),
Laromustine
(
CLORETATZNE
),
Lestaurtinib,
Lintuzumab,
Liposomal combination of cytarabine and daunorubicin
(
VYXEOS
),
Liposomal daunorubicin,
Midostaurin
(
RYDAPT
),
Mitoxantrone
(
NOVANTRONE
),
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide,
N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1- b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt,
N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride,
NEDD8-activating enzyme (NAE) inhibitor,
Onvansertib,
P-ethoxy growth factor receptor-bound protein 2 (Grb2) antisense oligonucleotide,
Plerixafor
(
MOZOBIL
),
Pracinostat,
Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,
Recombinant human interleukin-3 truncated diphtheria toxin fusion protein
(
ELZONRIS
),
Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide,
Sapacitabine,
Selinexor
(
XPOVIO
),
Tamibarotene,
Tipifarnib
(
ZARNESTRA
),
Tosedostat,
Troxacitabine,
Ulocuplumab,
Vadastuximab talirine,
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3),
Venetoclax
(
VENCLEXTA,
VENCLYXTO
),
Volasertib,
Vosaroxin,
Wilms' tumour 1 (WT1) vaccine,
Zosuquidar trihydrochloride,
cenisertib,
cusatuzumab,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate,
humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47,
lysine-specific histone demethylase (LSD1, also known as KDM1A) inhibitor
Registered!
A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with radiation. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. Patients frequently present with multilineage dysplasia and cytopenias 5-10 years after exposure.